Dupixent EOE denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Dupixent for EoE

Quantity limit (QL) denials for Dupixent in eosinophilic esophagitis occur when a prescription is written for a supply, frequency, or fill quantity that exceeds what UHC's formulary QL allows for the EoE indication. UHC sets quantity limits based on the dosing regimen described in the FDA-approved prescribing label for EoE. A QL denial most commonly arises from: a prescription written for a different labeled indication's dosing schedule, a quantity-per-fill that differs from what the QL allows, or a refill requested sooner than the QL permits.

## Why This Denial Is Appealable

If the prescribed quantity is consistent with the FDA-approved dosing regimen for EoE — which you should confirm directly in the current prescribing label — the QL denial is contestable. If the patient's clinical circumstances require a modified supply (e.g., due to a change in administration site or clinical urgency), the prescriber can request a quantity limit exception with documented justification.

## Federal Appeal Framework

• Quantity limit exception: File before or simultaneously with a formal appeal. The prescriber attests that the prescribed quantity is medically necessary and consistent with the FDA-approved labeling.
• Internal appeal: File within the deadline on the denial notice. Attach the relevant section of the FDA-approved prescribing label showing the approved dosing regimen for EoE, and confirm that the prescription matches it exactly.
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeal. File within approximately four months of the final internal denial (confirm exact date on the denial notice). An IRO will compare the QL to the FDA label and standard of care.
• Expedited track: Available if the patient is currently symptomatic and delay poses a health risk.

## Documentation to Gather

1. FDA-approved prescribing label: The current label for dupilumab, specifically the dosing section for the EoE indication. 2. Prescription as written: Confirm the dose, frequency, and quantity match the FDA label for EoE exactly. If they differ, obtain a prescriber explanation. 3. Confirmed EoE diagnosis: Biopsy pathology, gastroenterologist's note. 4. Clinical justification if non-standard: If the prescribed quantity differs from the standard QL for any clinical reason, a prescriber letter explaining the medical necessity for that quantity.

## Criteria-Mapping Structure

Create a one-page table: column 1 lists the FDA-approved dosing schedule for EoE (from the current label), column 2 lists the prescription as written, column 3 lists UHC's quantity limit. If columns 1 and 2 match but column 3 is more restrictive than the label, state that explicitly. This documents the core argument — that UHC's QL is more restrictive than the FDA label for this indication — and frames the external review argument if the internal appeal fails.